

VHL Research

James Gnarra, Ph.D.
University of Pittsburgh

Types of cancer-associated genes

Oncogenes

Normal protein function is to stimulate cell proliferation
Mutational ACTIVATION results in uncontrolled cell proliferation

Tumor Suppressors

Normal protein function is to suppress cell proliferation
Mutational INACTIVATION results in uncontrolled cell proliferation

DNA Repair Genes

Normal protein function is to repair DNA damage
Mutational INACTIVATION results in genome instability


Syndromes associated with inherited renal carcinoma

Syndrome	Histological type	Other neoplasias	Gene
Von Hippel-Lindau Disease (VHL)	Clear cell RCC	Retinal & CNS hemangioblastomas, pheochromocytomas, pancreatic cysts and neuroendocrine tumors	<i>VHL</i> , 3p25.5
Hereditary papillary RCC (HPRC)	Type 1 papillary RCC	Papillary thyroid carcinoma (rare)	<i>MET</i> , 7q31
Hereditary leiomyomatosis RCC (HLRCC)	Type 2 papillary RCC	Uterine and cutaneous leiomyoma	<i>FH</i> , 1q42-43
Birt-Hogg-Dube' syndrome (BHD)	Chromophobe RCC; Oncocytic RCC; Oncocytoma	Fibrolfolliculoma, lung cysts, spontaneous pneumothoraces, ?colon polyps	<i>BHD</i> , 17p11.2
Tuberous Sclerosis	Chromophobe RCC	Hamartomas, renal cysts & angiomyolipomas	<i>TSC1</i> <i>TSC2</i>

Significant Findings Related to VHL

1971 Knudson tumor suppressor gene hypothesis

Knudson's 2-Hit Model for Tumorigenesis



Significant Findings Related to VHL

1971 Knudson tumor suppressor gene hypothesis

1988 VHL gene mapped to chromosome 3p25-26

1993 Identification of the VHL gene


1994 VHL gene mutations in sporadic clear cell RCC

1994 Reliable methods to detect VHL gene mutations

1995 VHL gene mutations correlate with phenotype

1998 Reliable methods to detect VHL gene deletions


VHL germline point mutations



Significant VHL Findings Biochemistry


- 1995 VHL protein forms a complex with Elongin and other proteins

The pVHL E3 Ubiquitin Ligase Complex



Significant VHL Findings Biochemistry




- 1995 VHL protein forms a complex with Elongin and other proteins
- 1999 Crystal structure VHL-Elongin complex



From Stebbins et al, Science, 284, 455-461, 1999.

Significant VHL Findings Biochemistry

- 1995 VHL protein forms a complex with Elongin and other proteins
- 1999 Crystal structure VHL-Elongin complex
- 1999 VHL is an E3 ubiquitin ligase
- 1999 VHL regulates HIF protein levels




- ### Significant VHL Findings
- #### Cell Biology
- 1998 VHL associates with fibronectin
 - 1999 VHL controls cell motility and invasion
 - 2001 VHL regulates cell-cell and cell-extracellular matrix interactions
 - 2006 VHL regulates primary cilium formation and cystogenesis
 - 2008 VHL associates with collagen

Cellular phenotypes associated with VHL inactivation in RCC cells

Cell morphology	Epithelial	Mesenchymal
Extracellular matrix	Organized	Disorganized
E-cadherin	Positive	Negative
Cytoskeleton	Stable	Unstable
Adhesion	Increased	Decreased
Motility	Decreased	Increased


Kaelin, W.G., Jr. von Hippel-Lindau Disease, *Annu. Rev. Pathol. Mech. Dis.* 2007;2:145-173

- ### Significant VHL Findings
- #### Cell Biology
- 1996 Molecular link between VHL and angiogenesis



Significant Findings Related to VHL


- 2005 Sorafenib (VEGF R small molecule inhibitor) approved by FDA for advanced RCC
- 2006 Sunitinib (VEGF R small molecule inhibitor) approved by FDA for advanced RCC
- 2007 Temsirolimus (mTOR inhibitor) approved by FDA for advanced RCC



A significant new resource for research


Normal and tumor tissue from the NDRI

Protein expression analysis
Gene mutation analysis







Johns Hopkins University School of Medicine Tissue MicroArray Facility



Johns Hopkins University School of Medicine Tissue MicroArray Facility



Johns Hopkins University School of Medicine Tissue MicroArray Facility



Yale University School of Medicine Tissue MicroArray Facility

Thank You